A Phase I Clinical Study of BBI608 Administered with Paclitaxel in Patients with Previously treated Unresectable/Recurrent Gastric Cancer

Trial Profile

A Phase I Clinical Study of BBI608 Administered with Paclitaxel in Patients with Previously treated Unresectable/Recurrent Gastric Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2017

At a glance

  • Drugs Napabucasin (Primary) ; Paclitaxel
  • Indications Gastric cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Sumitomo Dainippon Pharma
  • Most Recent Events

    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 Status changed from not yet recruiting to completed, as reported at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 01 Jun 2015 Results from this study will be presented at the 2015 annual meeting of the American Society of Clinical Oncology, according to a Boston Biomedical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top